BioPharma Dive May 30, 2024
Akili, which makes a video game treatment for ADHD, will merge with Virtual Therapeutics to create a larger digital health organization.
Dive Brief:
- Akili, a company that makes a video game treatment for ADHD, will sell to Virtual Therapeutics for about $34 million, according to a Wednesday regulatory filing.
- The two companies will merge into a larger digital health firm, with Akili operating as a subsidiary of Virtual Therapeutics.
- Akili received Food and Drug Administration clearance in 2020 for a prescription game to improve attention in children with ADHD. But, after rounds of layoffs, the company shifted away from the prescription model last year and began exploring strategic alternatives in April.
Dive Insight:
Akili was one...
Today's Sponsors
Today's Sponsor